These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21620656)

  • 1. Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts.
    Joviliano EE; Piccinato CE; Dellalibera-Joviliano R; Moriya T; Évora PR
    Ann Vasc Surg; 2011 Aug; 25(6):846-55. PubMed ID: 21620656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukins and inflammatory markers in in-stent restenosis after femoral percutaneous transluminal angioplasty.
    Araújo PV; Ribeiro MS; Dalio MB; Rocha LA; Viaro F; Dellalibera Joviliano R; Piccinato CE; Évora PR; Joviliano EE
    Ann Vasc Surg; 2015; 29(4):731-7. PubMed ID: 25725274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Interleukins and Inflammatory Markers in the Early Restenosis of Covered Stents in the Femoropopliteal Arterial Segment.
    Guimaraes TS; da Rocha LA; Becari C; Piccinato CE; Joviliano RD; Ribeiro MS; Joviliano EE
    Ann Vasc Surg; 2018 Jul; 50():88-95. PubMed ID: 29481941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the kallikrein-kinin system, metalloproteinases, and their tissue inhibitors in the in-stent restenosis after peripheral percutaneous angioplasty.
    Ribeiro MS; Dellalibera-Joviliano R; Becari C; Teixeira FR; Araujo PV; Piccinato CE; Campos CP; Evora PR; Joviliano EE
    Ann Vasc Surg; 2014 May; 28(4):1005-15. PubMed ID: 24440188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restenosis after stenting of atherosclerotic renal artery stenosis: is there a rationale for the use of drug-eluting stents?
    Zeller T; Rastan A; Rothenpieler U; Müller C
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):125-30. PubMed ID: 16755597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous revascularization of persistent renal artery in-stent restenosis.
    Patel PM; Eisenberg J; Islam MA; Maree AO; Rosenfield KA
    Vasc Med; 2009 Aug; 14(3):259-64. PubMed ID: 19651676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of stents, drug-eluting stents, and stent-grafts in treatment of infrainguinal arterial disease.
    Tang GL; Morasch MD
    Semin Vasc Surg; 2007 Mar; 20(1):37-41. PubMed ID: 17386362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug eluting stents and modern stent technologies for in-stent restenosis.
    Werner M
    J Cardiovasc Surg (Torino); 2017 Aug; 58(4):497-500. PubMed ID: 28382805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents and drug-coated balloons in peripheral artery disease.
    Buechel R; Stirnimann A; Zimmer R; Keo H; Groechenig E
    Vasa; 2012 Jul; 41(4):248-61. PubMed ID: 22825858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.
    Li JJ; Li J; Nan JL; Li Z; Zhen X; Mu CW; Dai J; Zhang CY
    Med Hypotheses; 2007; 69(5):1004-9. PubMed ID: 17499449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-eluting stents in non-coronary arteries].
    Scalise F; Auguadro C; Manfredi M; Specchia G
    G Ital Cardiol (Rome); 2010 Oct; 11(10):753-60. PubMed ID: 21246776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balloon-expandable covered stent therapy of complex endovascular pathology.
    Giles H; Lesar C; Erdoes L; Sprouse R; Myers S
    Ann Vasc Surg; 2008 Nov; 22(6):762-8. PubMed ID: 18922676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the kallikrein-kinin system, matrix metalloproteinases, and tissue inhibitors of metalloproteinases in the early restenosis of covered stents in the femoropopliteal arterial segment.
    Rocha LA; Piccinato CE; Ribiero MS; Becari C; Joviliano RD; Joviliano EE
    J Vasc Surg; 2017 Jan; 65(1):119-127. PubMed ID: 27667150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Past, present and future of femoropopliteal stenting.
    Schillinger M; Minar E
    J Endovasc Ther; 2009 Feb; 16 Suppl 1():I147-52. PubMed ID: 19317587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents: a comprehensive appraisal.
    Butt M; Connolly D; Lip GY
    Future Cardiol; 2009 Mar; 5(2):141-57. PubMed ID: 19371189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.